CombiMatrix Corporation and Clarient, Inc. have jointly announced establishment of a strategic partnership to market and sell a genomics-based cancer test called HemeScan™, a comprehensive test related to the treatment and care of chronic lymphocytic leukemia (CLL), among other cancers.
According to both companies, the HemeScan test was developed by CombiMatrix and validated in collaboration with a team of high-profile academic centers, including the M.D. Anderson Cancer Center in Houston, the University of Texas Health Science Center in San Antonio, and Netherlands Cancer Institute in Amsterdam.
"The HemeScan test has proven to be a valuable and reliable clinical tool for the management of hematological malignancies (leukemia and lymphomas) and solid tumors characterized by unbalanced chromosomal rearrangements," said Shelly Gunn, M.D., Ph.D., Medical Director of Combimatrix Molecular Diagnostics (CMDX), a subsidiary of CombiMatrix Corporation.
Gunn continued, "Along with CLL, the HemeScan test has also been clinically validated for acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS) and is currently being tested for multiple myeloma (MM)."
"The HemeScan test will be marketed by Clarient to pathologists, oncologists, and patients," said Mansoor Mohammed, Ph.D., President and CEO of CMDX.
"In choosing our first partner to market our transformative HemeScan test, we felt that Clarient's cancer-focused brand is an ideal fit. Clarient is a nationally recognized cancer diagnostic service laboratory and deploys an expert national sales force with strong relationships with community pathologists and oncologists. We are pleased to have such a preeminent partner market our product and aid in its wide-scale adoption."
The HemeScan test is a comprehensive test enabling prognosis at the time of diagnosis in the treatment and care of CLL patients. The test provides prognostic marker precision with simultaneous diagnostic monitoring of the entire genome in CLL.
The HemeScan test is an approach to the management of CLL. In a single test, it can assay all of the genomic loci for copy number aberrations currently measured by commercial multi-probe fluorescent in situ hybridization (FISH) kits.
Moreover, by incorporating recently-identified genomic markers and a global genome perspective, the Companies believe the HemeScan test has the potential to have a transformative impact on the clinical stratification of CLL, enabling prognosis at diagnosis and patient-appropriate risk adapted treatment.